LTI-002 / Leukogene Therap - LARVOL DELTA

MHC class II targeted immunotherapy in the treatment of pancreatic cancer (AACR 2026) - "We observed synergy in combination with PDAC standard of care agents like gemcitabine, RAS(ON) inhibitors, and anti-PD1 immunotherapy. This study demonstrates the therapeutic potential of targeting MHCII to stimulate anti-PDAC immunity."

IO biomarker • Tumor mutational burden • Microsatellite Instability • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD4 • HLA-DRB1 • MSI • MSLN • TMB